For US residents only.


TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) is now FDA-approved as an adjuvant treatment for BRAF+ melanoma after surgery

Important Safety Information:

TAFINLAR and MEKINIST may cause serious side effects, including the risk of new cancers: TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cel...

See More
Approved Use:

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.


TAFINLAR, in combination with MEKINIST, is not used to tre...

See More